Stockreport

BeyondSpring Enrolls First Patient in Global Phase 3 Clinical Trial with Plinabulin in combination with G-CSF to Prevent Chemotherapy-Induced Neutropenia

BeyondSpring, Inc. - Ordinary Shares  (BYSI) 
Last beyondspring, inc. - ordinary shares earnings: 4/30 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.beyondspringpharma.com
PDF NEW YORK, Oct. 23, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncolo [Read more]